Telix Pharmaceuticals (Telix Pharmaceuticals) FCF Margin % : 1.02% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Telix Pharmaceuticals's Free Cash Flow for the six months ended in Dec. 2023 was $1.9 Mil. Telix Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was $186.3 Mil. Therefore, Telix Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 1.02%.

As of today, Telix Pharmaceuticals's current FCF Yield % is 0.26%.

The historical rank and industry rank for Telix Pharmaceuticals's FCF Margin % or its related term are showing as below:

TLPPF' s FCF Margin % Range Over the Past 10 Years
Min: -10640.51 Med: -366.43 Max: 35
Current: 2.64

During the past 9 years, the highest FCF Margin % of Telix Pharmaceuticals was 35.00%. The lowest was -10640.51%. And the median was -366.43%.

TLPPF's FCF Margin % is ranked better than
81.36% of 1041 companies
in the Biotechnology industry
Industry Median: -141.21 vs TLPPF: 2.64

Telix Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Telix Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals FCF Margin % Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-683.00

35.02

-1,238.47

-49.90

2.64

Telix Pharmaceuticals Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial								-1,121.52	-308.35	-6.30	4.70	1.02

Competitive Comparison of Telix Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Telix Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telix Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's FCF Margin % falls into.

Telix Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Telix Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	8.762	/	332.436
	=	2.64 %

Telix Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1.901	/	186.311
	=	1.02 %

Telix Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.